恶性肿瘤患者新冠病毒疫苗接种的专家意见  

Expert advice on novel coronavirus vaccination in patients with malignant tumors

作　　者：袁静[1] 谭晓华 王福祥 王绿化[2] 卢洪洲 Yuan Jing;Tan Xiaohua;Wang Fuxiang;Wang Lyuhua;Lu Hongzhou(The Third People's Hospital of Shenzhen,Guangdong Shenzhen 518112,China;Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center,Guangdong Shenzhen 518172,China)

机构地区：[1]深圳市第三人民医院,广东深圳518112 [2]中国医学科学院肿瘤医院深圳医院,广东深圳518172

出　　处：《新发传染病电子杂志》2022年第2期1-5,共5页Electronic Journal of Emerging Infectious Diseases

基　　金：国家自然科学基金(32001038);“十四五”国家重点研发计划(2021YFC2301803);广东省高水平临床重点专科深圳市配套建设经费(SZGSP011);深圳市科技创新委员会抗疫专项(JSGG20220301090005007);深圳市第三人民院院内课题(G2021027)。

摘　　要：新型冠状病毒感染肆虐全球,有效的新冠病毒疫苗接种不仅可以降低新型冠状病毒的感染率,同时也可以降低感染后的疾病严重程度及病死率。有效的疫苗接种对免疫抑制人群尤为重要,但目前国内对恶性肿瘤患者新冠病毒疫苗接种的有效性和安全性认识仍然不足,导致该类人群疫苗接种率低。因此,基于恶性肿瘤患者接种新冠病毒疫苗的国内外研究进展和临床治疗需求,特制订此专家意见。本文将全面依据恶性肿瘤患者的肿瘤种类、抗癌治疗方案和阶段以及病情等复杂因素,详细提出该类人群的新冠病毒疫苗接种建议,以提高恶性肿瘤患者的新冠病毒疫苗接种率,有效保护恶性肿瘤患者,降低其因新型冠状病毒所致的感染率、重症率、死亡率。Since SARS-CoV-2 infection remains to be a global pandemic,effective vaccination strategies were urgent to reduce the infection rate of SARS-CoV-2,attenuate the progress of the disease,and decrease the mortality after infection,which is particularly important for immunosuppressed patients.However,the efficacy and safety of SARS-CoV-2 vaccination in patients with malignant tumor are not well investigated in China,therefore,leading to a low SARS-CoV-2 vaccination coverage in patients with malignant tumor.According to the most recent researches and clinical treatment demands of SARS-CoV-2 vaccination for patients with malignant tumors,we summarized a detailed SARS-CoV-2 vaccination regimen for malignant tumors patients with different types of tumor,distinct anticancer treatment plan,as well as specialized the disease condition,so as to improve SARS-CoV-2 vaccines coverage,effectively protect patients,and reduce the susceptibility,severity and mortality of SARS-CoV-2 infection in patients with malignant tumors.

关 键 词：恶性肿瘤 新型冠状病毒 疫苗接种 专家意见 

分 类 号：R730.1[医药卫生—肿瘤] R186[医药卫生—临床医学]